Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05941897
Other study ID # AZ-RU-00001
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date June 21, 2023
Est. completion date July 29, 2025

Study information

Verified date May 2024
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A study to investigate efficacy and safety of ceralasertib plus durvalumab in participants aged ≥ 18 years with advanced or metastatic non-small cell lung cancer whose disease progressed on or after prior anti-PD-(L)1 therapy and platinum-based chemotherapy.


Description:

This is a single-arm study, all participants will be assigned to one treatment group - ceralasertib plus durvalumab combination therapy. Each 28-day cycle will begin with ceralasertib administered orally followed by durvalumab administered intravenously. The objectives of the current single-arm local study are to estimate the efficacy and safety of ceralasertib and durvalumab combination in local population to obtain relevant information for routine clinical practice. The results of this additional study will provide clinical data on efficacy and safety of an innovation drug in the new region - Russian Federation.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 39
Est. completion date July 29, 2025
Est. primary completion date July 29, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically documented NSCLC that is locally advanced or metastatic according to Version 8 of the IASLC Staging Manual in Thoracic Oncology. - Documented epidermal growth receptor factor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type status. - Documented radiological PD whilst on or after receiving the most recent treatment regimen. - Eligible for second- or third-line therapy and must have received an anti-PD-(L)1 therapy and a platinum doublet containing therapy for locally advanced or metastatic NSCLC. - Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status of 0 or 1. - Adequate organ function and marrow reserve. - Body weight > 30 kg and no cancer-associated cachexia. Exclusion Criteria: - Participant with mixed SCLC and NSCLC histology. - Brain metastases or spinal cord compression unless the participant is stable and off steroids. - Persistent toxicities (CTCAE Grade > 2) caused by previous anticancer therapy. - Active or prior documented autoimmune or inflammatory disorders. - History of leptomeningeal carcinomatosis. - Participants who have received more than one line of prior anti-PD-(L)1. - Participants must not have experienced a toxicity that led to discontinuation of the prior anti-PD(L)1 therapy. - Participants must not have experienced a Grade = 3 immune-mediated adverse event (imAE) or an immune-related neurologic or ocular AE of any grade while receiving prior anti-PD(L)1 therapy. - Participants must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged. - Participants who have received more than one prior line of platinum-based chemotherapy in metastatic setting. - As judged by the investigator, any evidence of medical condition, which, in the investigator's opinion, makes it undesirable for the participant to participate in the study. - Participants who have received a prior ATR inhibitor. - Diagnosis of ataxia telangiectasia.

Study Design


Intervention

Drug:
Ceralasertib
Participants will receive ceralasertib oral tablets.
Durvalumab
Participants will receive durvalumab as an intravenous infusion

Locations

Country Name City State
Russian Federation Research Site Moscow
Russian Federation Research Site Moscow
Russian Federation Research Site Moscow
Russian Federation Research Site Moscow
Russian Federation Research Site Moscow
Russian Federation Research Site Nizhny Novgorod
Russian Federation Research Site Saint Petersburg
Russian Federation Research Site St. Petersburg
Russian Federation Research Site St. Petersburg

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate (ORR) Objective response rate (ORR) is defined as the proportion of participants who have a complete response (CR) or partial response (PR) per RECIST 1.1. At month 6 after the last patient's first dose (approximately 18 months).
Secondary Duration of Response (DoR) DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1. Up to 30 months
Secondary Time to response (TTR) Time to response (TTR) is defined as the time from the start of treatment until the date of first documented objective response per RECIST 1.1. Up to 30 months
Secondary Disease control rate (DCR) DCR at 18 weeks is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) for at least 17 weeks per RECIST 1.1. At month 6 after the last patient's first dose (approximately 18 months).
Secondary Progression free survival (PFS) PFS is defined as time from the start of treatment until progression per Response Evaluation Criteria in Solid Tumours, Version 1.1 (RECIST 1.1). Up to 30 months
Secondary Overall survival (OS) OS is defined as time from the start of treatment until the date of death due to any cause. Up to 30 months
Secondary Number and percentage of AEs in patients receiving Ceralasertib and Durvalumab combination The safety and tolerability profile of Ceralasertib and Durvalumab combination will be evaluated using vital signs, laboratory data, electrocardiograms (ECGs), and adverse event data Up to 30 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04526691 - Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) Phase 1
Recruiting NCT05435248 - Hase 1/2 Study of HS-10375 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) Phase 1/Phase 2
Not yet recruiting NCT04942301 - PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy Phase 1
Recruiting NCT04612751 - Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03673332 - Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies Phase 4
Completed NCT04177290 - A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients Phase 1